Journals / Turkish Neurosurgery / 2013 / Cilt: 23 - Sayı: 6

Beyinde Kitle Lezyonları: Tümör mü multipl Skleroz mu? Bir multipl Skleroz Başvuru merkezi Sonuçları: Klinik,görüntüleme Özellikleri ve Seyir

Mass lesions in the Brain: tumor or Multiple Sclerosis? Clinical and Imaging Characteristics and Course from a Single Reference Center

Pages
728–735
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A higher MS conversion rate was found in patients with a younger TDL onset age.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: In demyelinating disease spectrum, tumor-like (tumefactive) demyelinating lesions (TDL) are rarely seen.
📊
Key Findings & Data:MATERIAL and METHODS: 25 patients with TDL in our center were followed and clinical, magnetic resonance imaging (MRI), magnetic resonance spectroscopy, cerebrospinal fluid (CSF) findings and disease course were retrospectively evaluated. results: Mean age at symptom onset was 29 years.
💡
Conclusion & Impact:A higher MS conversion rate was found in patients with a younger TDL onset age.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: In demyelinating disease spectrum, tumor-like (tumefactive) demyelinating lesions (TDL) are rarely seen. Atypical imaging and clinical features of these lesions may cause misdiagnosis of tumor or abscess. MATERIAL and METHODS: 25 patients with TDL in our center were followed and clinical, magnetic resonance imaging (MRI), magnetic resonance spectroscopy, cerebrospinal fluid (CSF) findings and disease course were retrospectively evaluated. results: Mean age at symptom onset was 29 years. Motor and sensory deficits were most common symptoms and 18 of them were polysymptomatic. Mostly frontal and parietal regions were affected. 10/25 patients were initially misdiagnosed clinically as brain abscess, primary central nervous system tumor metastasis. T2-hypointense rim, incomplete ring enhancement of the lesions on post-gadolinium T1- weighted imaging on brain MRI enabled accurate diagnosis of TDLs. 13 of 21 patients with first-TDL presentation sustained a monophasic course, remaining 8 patients converted to multiple sclerosis (MS) at a mean 38.4 months follow-up. Clinical isolated syndrome (CIS) patients were older than patients who developed MS and Expanded Disability Status Scale was lower (0.96 vs 3.7). CONCLUSION: Although MRI, CSF and pathologic examination help in differential diagnosis of the mass lesions, close follow-up is still crucial for the definite diagnosis. A higher MS conversion rate was found in patients with a younger TDL onset age.

Özet

AMAÇ: Demiyelinizan hastalık spekturumunda olan tümör benzeri (tümefaktif) demiyelinizan lezyonlar (TDL) nadiren görülmektedir. Atipik görüntüleme ve klinik özellikler yanlışlıkla tümör veya abse tanısı konmasına neden olabilmektedir. YÖNTEM ve GEREÇLER: Merkezimizde takipli 25 TDL hastasının klinik, manyetik rezonans görüntüleme (MRG), manyetik rezonans spektroskopi (MRS), beyin omurilik sıvısı (BOS) bulguları ve hastalık seyri retrospektif olarak değerlendirilmiştir. Hastalar başlangıçta TDL olanlar (n=21) ve demiyelinizan hastalık sürecinde TDL olanlar (n=4) olmak üzere iki gruba ayrılmıştır. BULGULAR: Hastaların semptom başlangıcında ortalama yaşları 29 olarak hesaplanmıştır. Motor ve duysal kayıp en sık görülen semptomlardı.18 hastada semptomlar polisemptomatikti. Lezyonlar çoğunlukla frontal ve parietal bölgelerdeydi. 10/25 hastada klinik olarak ilk tanı beyin absesi, primer santral sinir sistemi tümörü ve metastaz olarak konmuştu. T2-hipontens rim ve kontrastlı T1 kesitlerde inkomplet halka varlığı TDL kesin tanısında yardımcı bulgulardı. TDL başlangıçlı 21 hastanın 13ünde monofazik seyir görülmüş, kalan 8 hasta ortalama 38,4 aylık takip sürecinde multiple skleroza (MS) dönüşüm göstermişti. Klinik izole sendrom (KİS) hastalarının ise MSe dönen hastalardan daha yaşlı oldukları ve Genişletilmiş Özürlülük Durum Ölçeği (EDSS) daha düşük olduğu saptanmıştır (0,96 vs 3.7). SONUÇ: MRG, BOS ve patolojik değerlendirme kitle ayırıcı tanısında yardımcı olmakla birlikte kesin tanı için halen yakın takip önem taşımaktadır. TDL genç yaşta görülen hastalarda MS e dönüşüm riski daha yüksek olduğu görülmüştür.

🔖

Cite This Article

KILIÇ, A. K., KURNE, A. T., OGUZ, K. K., SÖYLEMEZOĞLU, F., KARABUDAK, R. (2013). Beyinde Kitle Lezyonları: Tümör mü multipl Skleroz mu? Bir multipl Skleroz Başvuru merkezi Sonuçları: Klinik,görüntüleme Özellikleri ve Seyir. Turkish Neurosurgery, Cilt: 23 - Sayı: 6, 728–735. https://ajindex.com/articles/417850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER: Advanced MR Imaging Technics in the Diagnosis of Intraaxial Brain Tumors in Adults. RadioGraphics 26 Suppl 1:173-190, 2006 2. Fallah A, Banglawala S, Ebrahim S, Paulseth JE, Jha NK: Tumefactive demyelinating lesions: A diagnostic challenge. Can J Surg 53 (1): 69-70, 2010 3. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Adèr HJ, Losseff N, Valk J: Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069, 1997 4. Blasel S, Pfellschifter W, Jansen V, Mueller K, Zanella F, Hattingen E: Metabolism and regional cerebral blood volume in autoimmune inflammatory demyelinating lesions mimicking malignant gliomas. J Neurol 258 (1): 113-122, 2011 5. Butteris DJA, Ismail A, Ellison DW, Birchall D: Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis. Br J Radiol 76 (909):662-665, 2003 6. Cha S, Pierce S, Knopp EA, Johnson G, Yang C, Ton A, Litt AW, Zagzag D: Dynamic Contrast-enhanced T2*-weighted MR Imaging of Tumefactive Demyelinating Lesions. AJNR Am J Neuroradiol 22 (6):1109-1116, 2001 7. Cianfoni A, Niku S, Imbesi SG: Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28 (2):272-277, 2007 8. Dastgir J, DiMario FJ Jr: Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: Review of the literature and treatment proposal. J Child Neurol 24 (4):431-437, 2009 9. Enzinger C, Strasser-Fuchs S, Ropele S, Kapeller P, Kleinert R, Fazekas F: Tumefactive demyelinating lesions: Conventional and advanced magnetic resonance imaging. Mult Scler 11:135-139, 2005 10. Ernst T, Chang L, Walot I, Huff K: Physiologic MRI of a tumefactive multiple sclerosis lesion. Neurology 51 (5): 1486-1488, 1998 11. Given CA 2nd, Stevens BS, Lee C: The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 182(1):195-199, 2004 12. Jain R, Ellika S, Lehman NL, Scarpace L, Schultz LR, Rock JP, Rosenblum M, Mikkelsen T: Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT? J Neurooncol 97(3):383-388, 2010 13. Khoshyomn S, Braff SP, Penar PL: Tumefactive multiple sclerosis plaque. J Neurol